CDK9 inhibitor

DRUG CLASS:

CDK9 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	SLS009 Sensitive: B - Late Trials SLS009 Sensitive : B	SLS009 Sensitive: B - Late Trials SLS009 Sensitive : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	TG02 Sensitive: C2 – Inclusion Criteria TG02 Sensitive : C2	TG02 Sensitive: C2 – Inclusion Criteria TG02 Sensitive : C2
IDH1 mutation	Glioma	IDH1 mutation	Glioma	TG02 Sensitive: C3 – Early Trials TG02 Sensitive : C3	TG02 Sensitive: C3 – Early Trials TG02 Sensitive : C3
MCL1 amplification	Endometrial Cancer	MCL1 amplification	Endometrial Cancer	CYC065 Sensitive: C3 – Early Trials CYC065 Sensitive : C3	CYC065 Sensitive: C3 – Early Trials CYC065 Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	BTX-A51 Sensitive: C3 – Early Trials BTX-A51 Sensitive : C3	BTX-A51 Sensitive: C3 – Early Trials BTX-A51 Sensitive : C3
CDK1 overexpression	Adrenal Cortex Carcinoma	CDK1 overexpression	Adrenal Cortex Carcinoma	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
CDK2 overexpression	Adrenal Cortex Carcinoma	CDK2 overexpression	Adrenal Cortex Carcinoma	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
KRAS G12V	Colon Cancer	KRAS G12V	Colon Cancer	CDK9 inhibitor Sensitive: D – Preclinical CDK9 inhibitor Sensitive : D	CDK9 inhibitor Sensitive: D – Preclinical CDK9 inhibitor Sensitive : D
MCL1 expression	Acute Myelogenous Leukemia	MCL1 expression	Acute Myelogenous Leukemia	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
MCL1 expression	Myelodysplastic Syndrome	MCL1 expression	Myelodysplastic Syndrome	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
KRAS Q61H	Non Small Cell Lung Cancer	KRAS Q61H	Non Small Cell Lung Cancer	ME-522 Sensitive: D – Preclinical ME-522 Sensitive : D	ME-522 Sensitive: D – Preclinical ME-522 Sensitive : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	ME-522 Sensitive: D – Preclinical ME-522 Sensitive : D	ME-522 Sensitive: D – Preclinical ME-522 Sensitive : D
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	ME-522 Sensitive: D – Preclinical ME-522 Sensitive : D	ME-522 Sensitive: D – Preclinical ME-522 Sensitive : D
CD133 positive	Glioblastoma	CD133 positive	Glioblastoma	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D
CD44 positive	Glioblastoma	CD44 positive	Glioblastoma	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D
BRCA1 2080delA + CCNE1 overexpression	Breast Cancer	BRCA1 2080delA + CCNE1 overexpression	Breast Cancer	CYC065 Sensitive: D – Preclinical CYC065 Sensitive : D	CYC065 Sensitive: D – Preclinical CYC065 Sensitive : D
BRCA1 2080delA	Breast Cancer	BRCA1 2080delA	Breast Cancer	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D
BRCA1 R1443*	Breast Cancer	BRCA1 R1443*	Breast Cancer	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D
ASXL1 mutation	Myelodysplastic Syndrome	ASXL1 mutation	Myelodysplastic Syndrome	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
MYC expression	Ovarian Cancer	MYC expression	Ovarian Cancer	KB-0742 Sensitive: D – Preclinical KB-0742 Sensitive : D	KB-0742 Sensitive: D – Preclinical KB-0742 Sensitive : D
MYC amplification	Ovarian Cancer	MYC amplification	Ovarian Cancer	KB-0742 Sensitive: D – Preclinical KB-0742 Sensitive : D	KB-0742 Sensitive: D – Preclinical KB-0742 Sensitive : D
MYC amplification	Colon Cancer	MYC amplification	Colon Cancer	KB-0742 Resistant: D – Preclinical KB-0742 Resistant : D	KB-0742 Resistant: D – Preclinical KB-0742 Resistant : D
MYC amplification	Hepatocellular Cancer	MYC amplification	Hepatocellular Cancer	KB-0742 Resistant: D – Preclinical KB-0742 Resistant : D	KB-0742 Resistant: D – Preclinical KB-0742 Resistant : D
MYC amplification	Gastric Cancer	MYC amplification	Gastric Cancer	KB-0742 Resistant: D – Preclinical KB-0742 Resistant : D	KB-0742 Resistant: D – Preclinical KB-0742 Resistant : D
MYC amplification	Esophageal Cancer	MYC amplification	Esophageal Cancer	KB-0742 Resistant: D – Preclinical KB-0742 Resistant : D	KB-0742 Resistant: D – Preclinical KB-0742 Resistant : D
MYC amplification	Head and Neck Cancer	MYC amplification	Head and Neck Cancer	KB-0742 Resistant: D – Preclinical KB-0742 Resistant : D	KB-0742 Resistant: D – Preclinical KB-0742 Resistant : D
ZRSR2 mutation	Myelodysplastic Syndrome	ZRSR2 mutation	Myelodysplastic Syndrome	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	CDDD11-8 Sensitive: D – Preclinical CDDD11-8 Sensitive : D	CDDD11-8 Sensitive: D – Preclinical CDDD11-8 Sensitive : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	KB-0742 Sensitive: D – Preclinical KB-0742 Sensitive : D	KB-0742 Sensitive: D – Preclinical KB-0742 Sensitive : D
ASXL1 Y588X	Myelodysplastic Syndrome	ASXL1 Y588X	Myelodysplastic Syndrome	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
KMT2A rearrangement	B Acute Lymphoblastic Leukemia	KMT2A rearrangement	B Acute Lymphoblastic Leukemia	PRT2527 Sensitive: D – Preclinical PRT2527 Sensitive : D	PRT2527 Sensitive: D – Preclinical PRT2527 Sensitive : D
MYCN amplification	Rhabdomyosarcoma	MYCN amplification	Rhabdomyosarcoma	selinexor + VIP152 Sensitive: D – Preclinical selinexor + VIP152 Sensitive : D	selinexor + VIP152 Sensitive: D – Preclinical selinexor + VIP152 Sensitive : D

CDK9 inhibitor

CDK9 inhibitor

Associations(38)

Associations
(38)